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(range:15.1mm/h (France)-21.0mm/h (Italy)) and CRP (range:5.6mg/dl (Spain)-
12.5mg/dl (UK)). Current disease severity per physician-judgment 
(mild:moderate:severe) in 5EU were: UK-68%:22%:10%, Germany-57%:39%:5%, 
France-46%:47%:7%, Italy-64%:34%:2%, Spain-69%:27%:4%. Among patients with 
available data, current HAQ (range: 0.7(France)-1.5(Germany)), BASDAI 
(range:3.0(Spain)-3.4(UK)), 100mmVAS (range:19.0(France)-31.4(UK)) and Swollen 
Joint Count (range:0.5(France)-(3.7(UK)) differed within 5EU. Among patients with 
available data, response to current biologic per ASAS criteria were 
(%ASAS20:%ASAS40:ASAS5/6:%ASAS partial-remission): UK-12%:6%:0%:4%, 
Germany-20%:9%:9%:11%, France-13%:7%:7%:11%, Italy-30%:17%:13%:18%, Spain-
19%:13%:5%:13%. CONCLUSIONS: Among AS patients receiving their first 
biologic, disease severity differed within 5EU, with patients in the UK with 
relatively higher burden and poorer treatment response. Impact of specific 
biologic treatments on the observed patterns warrants further scrutiny.  
 
PMS10  
COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH 
PSORIATIC ARTHRITIS (PSA) RECEIVING THEIR FIRST BIOLOGIC IN UK, 
GERMANY, FRANCE, ITALY AND SPAIN (5EU)  
Narayanan S1, Lu Y2, Hutchings R2, Baskett A2 
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To compare the disease status and outcomes of patients with PsA 
receiving their first biologic in 5EU. METHODS: A multi-country multi-center 
medical chart-review study of PsA patients was conducted among physicians 
(rheumatologists:97%) in hospitals and private practices to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30 yrs) and patient volume 
(incl. >5PsA biologic patients/month) and recruited from a large panel to be 
geographically representative in each country. Eligible patient charts (>3) were 
randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient 
diagnosis, treatment patterns/dynamics and patient symptomatology/disease 
status/outcomes. RESULTS: In 1Q2012, 1099 eligible PsA patient charts were 
abstracted; 916 (83%) patients were on their first biologic (mean-age:48.1yrs, 
female:46%). Geographic distribution of patients were – UK:20%, Germany:18%, 
France:22%, Italy:21%, Spain:19%. Time-to-1st biologic from diagnosis 
(range:31month (Italy)-50month (UK)) and time-on-current biologic 
(range:19month (Italy)-24month (France)) differed within 5EU. The top-4 reasons 
for biologic treatment initiation across 5EU were ‘mechanism of action’, ‘improve 
signs/symptoms’, ‘preservation of structural damage’ and ‘positive personal 
experience’. Key lab measures documented were: ESR (range:18.6mm/h (France)-
25.2mm/h (Italy)) and CRP (range:6.3mg/dl (Spain)-14.5mg/dl (UK)). Current 
disease severity per physician-judgment (mild:moderate:severe) in 5EU were: 
UK-61%:25%:13%, Germany-57%:37%:6%, France-44%:46%:11%, Italy-56%:41%:2%, 
Spain-64%:33%:3%. Among patients with available data, current HAQ (range: 
0.7(Spain)-1.5(Germany)), BASDAI (range:2.7(Spain)-3.9(UK)), 100mmVAS 
(range:23.9(Spain)-31.4(UK)) and Swollen Joint Count (range:1.2(Spain)-(3.7(UK)) 
differed within 5EU. Among patients with available data, response to current 
biologic per ASAS criteria were (%ASAS20:%ASAS40:ASAS5/6:%ASAS partial-
remission): UK-8%:8%:0%:4%, Germany-18%:7%:9%:12%, France-11%:6%:6%:10%, 
Italy-29%:16%:12%:15%, Spain-13%:14%:9%:9%. CONCLUSIONS: Among PsA 
patients receiving their first biologic, disease severity and outcomes differed 
within 5EU, with patients in the UK with relatively higher burden and poorer 
treatment response. Impact of specific biologic treatments on the observed 
patterns warrants further scrutiny.  
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META-ANALYSIS FOR EFFICACY OF ETANERCEPT FOR TREATMENT OF 
PSORIATIC ARTHRITIS  
Aggarwal S, Topaloglu H, Messenger M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Psoriatic arthritis (PA) is an inflammatory disease affecting joints 
and connective tissues. The anti-tumor necrosis factor (TNF) biologics are 
increasingly being used in patients who have failed traditional disease-
modifying antirheumatic drugs. Etanercept has shown efficacy in treatment of 
PA. The objective of this study was to conduct meta-analysis and present total 
evidence for etanercept in treatment of PA. METHODS: For this meta-analysis we 
included randomized controlled trials (RCTs)evaluating etanercept for the 
treatment of PS. RCTs studying adult populations with active and progressive PA 
with an inadequate response to previous DMARD therapy were eligible. Trials 
conducted among PA populations with prior experience with anti-TNF agents, 
including an inadequate response, were excluded. A systematic literature search 
for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, 
interventions, year, and the three outcomes HAQ, PASI and PsARC. For meta-
analysis, random effects and fixed effects models were used to obtain 
cumulative statistics. RESULTS: Two RCTs with a total of 131 patients were 
identified. The pooled response rates for Etanercept for PsARC were 75% (95% CI 
60%-90%), for HAQ were 59% (95% CI 46%-72%), and for PASI were 24% (95% CI 
13%-34%). The pooled response rates for placebo for PsARC were 30% (95% CI 
26%-35%), for HAQ were 5% (95% CI 1%-9%), and for PASI were 3% (95% CI 0%-7%). 
For PsARC the cumulative relative risk with Etanercept versus placebo was 0.40 
(95% CI 33%-48%). For HAQ, the cumulative relative risk with Etanercept versus 
placebo was 0.08 (95% CI 5%-12%). For PASI, the cumulative relative risk with 
Etanercept versus placebo was 0.14 (95% CI 8%-20%). CONCLUSIONS: Meta-
analysis shows Etanercept offers patients with psoriatic arthritis an effective 
therapeutic option for control of their disease.  
PMS12  
STRUCTURING CRITERIA IN MULTI-CRITERIA DECISION MODELS FOR 
BENEFIT/RISK ASSESSMENT OF BIOLOGICS IN JUVENILE ARTHRITIS  
Satiti M1, IJzerman MJ1, Boere-Boonekamp M1, Bridges JFP2 
1University of Twente, Enschede, The Netherlands, 2Johns Hopkins Bloomberg School of Public 
Health, Baltimore, MD, USA  
OBJECTIVES: Multi-criteria decision analysis (MCDA) is a technique which is 
proposed for quantitative benefit/risk assessment. MCDA structures benefits and 
risks in a decision or value tree, either by forming hierarchical clusters of 
benefits and risks separately or by placing both benefits and risks on the same 
level allowing direct comparison of all benefits and risks (non-hierarchical). The 
objective of this study was to compare two approaches for structuring decision 
trees and to evaluate the rank-order of three TNF– inhibitors for Methotrexate 
type of Juvenile Idiopathic Arthritis (JIA). METHODS: The alternatives selected for 
evaluation were Etanercept, Infliximab and Adalimumab. Six criteria were 
identified for evaluation, including improvement in pain, improvement in social 
function, Methotrexate (MTX) discontinuation, administration reaction, serious 
infection and cancer. The criteria were structured both non–hierarchically and 
hierarchically. Two different questionnaires were developed and randomized to 
42 physicians in three hospitals. Weight elicitation was performed using the 
Analytic Hierarchy Process. RESULTS: In hierarchical structures, the criterion 
weights were more steep and the range between most and least important 
criterion was larger than in non-hierarchical structures. Risks were considered 
more important (aggregated wrisk=0.35) in an non-hierarchical structure than in 
an hierarchical structure (wrisk=0.20). Applying the performance weights for three 
TNF-a inhibitors showed that there is a different rank-order of drugs being 
considered. The weights elicited from non–hierarchical questionnaire showed 
Etanercept to be most preferred. Yet, Adalimumab was most preferred if a 
hierarchical structure was used. The non–hierarchical questionnaire could be 
transformed to a hierarchical structure after which a similar rank-order of drugs 
was found as in the hierarchical structure. CONCLUSIONS: The rank order of the 
alternatives indeed changes when the criteria were structured differently 
regardless where the criteria weights were obtained from similar or different 
group of participants. Policy implications need to be explored.  
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ASSESSING THE GEOGRAPHIC AND DEMOGRAPHIC VARIATION ASSOCIATED 
WITH PSORIATIC ARTHRITIS PREVALENCE IN THE VETERAN POPULATION IN 
THE UNITED STATES  
Wang L1, Huang A1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To study the relationship between psoriatic arthritis (PsA) 
prevalence and geographic variation and demographic characteristics in the U.S. 
veteran population. METHODS: Using the Veterans Health Administration (VHA) 
Medical SAS Datasets from October 1, 2005 to May 31, 2012, a retrospective 
database analysis was performed. All U.S. veteran beneficiaries diagnosed with 
PsA were identified using International Classification of Disease 9th Revision 
Clinical Modification (ICD-9-CM) diagnosis code 696.0. All patients with medical 
benefit enrollment in 2011 were included in the study. Descriptive statistics were 
calculated as means±standard deviation (SD) and percentages to measure age, 
race and other related factors in the sample. RESULTS: A total of 22,102 veterans 
were diagnosed with PsA during 2011. The state of Vermont had the highest 
prevalence rate (0.29%), followed by New Hampshire (0.23%), and Maine (0.23%). 
All other states were observed with prevalence rates lower than 0.2%. 
Washington D.C. had only three cases of the disease, which translated into 0.02% 
of prevalence. Patients age 55-64 were most likely to be diagnosed with PsA 
(0.15%). Prevalence was lower by 0.05% for patients age 35-54 and 65+ (0.10%). 
Younger patients were less likely to be diagnosed with the disease (<0.05%). PsA 
diagnoses also varied by race: Non-Hispanic White (0.14%), Hispanic (0.12%), 
Non-Hispanic Black (0.03%), and other races (0.08%). CONCLUSIONS: PsA was 
unevenly distributed across the United States when measured by age group and 
race. Geographic variation was also related to disease occurrence. These factors 
should be taken into consideration for further studies.  
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ANNUAL MORTALITY IN A LARGE PREVALENCE-BASED SAMPLE OF UNITED 
STATES RHEUMATOID ARTHRITIS PATIENTS  
Palmer LA, Farr A, Johnston SS 
Truven Health Analytics, Washington, DC, USA  
OBJECTIVES: Studies estimating mortality rates in United States rheumatoid 
arthritis (RA) patients have largely been based upon registry or single-center 
populations numbering in the hundreds or few thousands of RA patients, which 
limits the generalizability of their findings. The objective of this study was to 
describe annual mortality in a large prevalence-based sample of U.S. RA patients. 
METHODS: This was a retrospective study based on mortality data obtained from 
the Social Security Administration (SSA) linked to approximately 15 million 
individuals present in the Truven Health MarketScan® Commercial and Medicare 
Supplemental administrative claims databases. The SSA data currently include 
information on whether individuals were living or had died (including date of 
death) as of October 31, 2012. To maximize generalizability, this study used a 
prevalence-based sampling technique whereby RA patients representing a broad 
spectrum of disease durations and severity were selected. To that end, patients 
aged 18+ years were selected for study if they were continuously enrolled in 
insurance benefits throughout calendar year 2010 and during this time period 
had at ≥1 medical claim with an ICD-9-CM code for RA (714.0x). Claims that may 
have represented efforts to ‘rule out’ the presence of RA were excluded from 
consideration. The study outcome was age/sex-specific mortality rates in 2011. 
